Medirama-Anticancer Therapy Research Association, MOU for Anticancer Clinical Research
Moon Hanlim, CEO of Medirama (left), and Jang Daeyoung, President of the Korean Association for Anticancer Therapy, are posing for a commemorative photo after signing an MOU. (Photo by Medirama)
View original image[Asia Economy Reporter Chunhee Lee] Medirama announced on the 20th that it has signed a memorandum of understanding (MOU) with the Korean Association for Cancer Chemotherapy to establish a cooperative relationship for the mutual development of both organizations and to collaborate on clinical research and development (R&D) related to anticancer treatment.
Both organizations plan to cooperate in various areas, including sharing information on anticancer drug candidates requiring clinical development, collaborating on symposiums to develop clinical experts in anticancer drugs, and sharing the latest trends regarding the U.S. Food and Drug Administration (FDA) standards for new anticancer drug approvals.
The Korean Association for Cancer Chemotherapy is a leading multi-institutional cancer clinical research group in Korea, primarily composed of oncologists. It actively conducts cancer clinical trials aimed at developing new cancer treatments based on a nationwide network of cancer researchers and international research groups.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Jang Daeyoung, chairman of the Korean Association for Cancer Chemotherapy, stated, “Through this MOU, we expect to develop cancer treatments that can help domestic cancer patients by receiving Medirama’s professional clinical advice and to establish successful cancer treatment strategies.” Moon Hanlim, CEO of Medirama, also said, “We are very pleased to have the opportunity to explore various collaborations with the Korean Association for Cancer Chemotherapy for the clinical development of anticancer drugs developed by domestic and international biotech companies. We will strive to maximize synergy with the Korean Association for Cancer Chemotherapy.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
